留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

非小细胞肺癌罕见靶点靶向治疗最新研究进展

李国雨 何明

李国雨, 何明. 非小细胞肺癌罕见靶点靶向治疗最新研究进展[J]. 协和医学杂志, 2021, 12(2): 268-274. doi: 10.3969/j.issn.1674-9081.2020.00.019
引用本文: 李国雨, 何明. 非小细胞肺癌罕见靶点靶向治疗最新研究进展[J]. 协和医学杂志, 2021, 12(2): 268-274. doi: 10.3969/j.issn.1674-9081.2020.00.019
LI Guo-yu, HE Ming. Research Progress of Targeted Therapy at Rare Targets for Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 268-274. doi: 10.3969/j.issn.1674-9081.2020.00.019
Citation: LI Guo-yu, HE Ming. Research Progress of Targeted Therapy at Rare Targets for Non-small Cell Lung Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 268-274. doi: 10.3969/j.issn.1674-9081.2020.00.019

非小细胞肺癌罕见靶点靶向治疗最新研究进展

doi: 10.3969/j.issn.1674-9081.2020.00.019
详细信息
    通讯作者:

    何 明  电话:0311-66696325,E-mail: 2935883213@qq.com

  • 中图分类号: R734.2

Research Progress of Targeted Therapy at Rare Targets for Non-small Cell Lung Cancer

More Information
  • 摘要: 靶向治疗的快速发展,使非小细胞肺癌(non-small cell lung cancer, NSCLC)的治疗取得革命性突破。相较于放化疗,靶向治疗可显著提高NSCLC患者的5年生存率,改善其预后。靶向治疗针对的靶点除常见的表皮生长因子受体(epidermal growth factor receptor, EGFR)突变基因外,我国肺癌人群中还存在诸多罕见靶点,如间变性淋巴瘤激酶(anaplastic lymphoma kinase, ALK)、间质表皮转化因子(mesenchymal to epithelial transition factor, MET)、人表皮生长因子受体2(human epidermal growth factor receptor 2, HER2)等。近年来,针对这些罕见靶点的新型药物不断更新、相继进入临床使用,并取得了令人惊艳的疗效。本文对以ALK、MET、HER2为靶点的靶向治疗最新研究进展进行梳理和总结,以期为NSCLC的临床治疗提供借鉴。
    作者贡献:李国雨负责查阅文献、撰写论文;何明负责论文审阅与修改。
    利益冲突:  无
  • [1] 郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41: 19-28. doi:  10.3760/cma.j.issn.0253-3766.2019.01.005
    [2] 郑轩, 胡毅. 晚期非小细胞肺癌患者抗PD-1治疗前后血清TNF-α水平变化与疗效的关系[J]. 解放军医学院学报, 2019, 40: 231-234. doi:  10.3969/j.issn.2095-5227.2019.03.008
    [3] Genova C, Rossi G, Tagliamento M, et al. Targeted therapy of oncogenic-driven advanced non-small cell lung cancer: recent advances and new perspectives[J]. Expert Rev Respir Med, 2020, 14: 367-383. doi:  10.1080/17476348.2020.1714441
    [4] Atal S, Asokan P, Jhaj R. Recent advances in targeted small-molecule inhibitor therapy for non-small-cell lung cancer-An update[J]. J Clin Pharm Ther, 2020, 45: 580-584. doi:  10.1111/jcpt.13121
    [5] Singh SS, Dahal A, Shrestha L, et al. Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy[J]. Curr Med Chem, 2020, 27: 5274-5316. doi:  10.2174/0929867326666190222183219
    [6] Arbour KC, Riely GJ. Systemic Therapy for Locally Adv-anced and Metastatic Non-Small Cell Lung Cancer: A Review[J]. JAMA, 2019, 322: 764-774. doi:  10.1001/jama.2019.11058
    [7] Iwama E, Goto Y, Murakami H, et al. Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401[J]. Oncologist, 2020, 25: 306-e618. doi:  10.1634/theoncologist.2019-0728
    [8] Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study[J]. Anna Oncoly, 2020, 31: 1056-1064. doi:  10.1016/j.annonc.2020.04.478
    [9] Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial[J]. Lancet, 2017, 390: 29-39. doi:  10.1016/S0140-6736(17)30565-2
    [10] Zhou C, Kim SW, Reungwetwattana T, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study[J]. Lancet Respir Med, 2019, 7: 437-446. doi:  10.1016/S2213-2600(19)30053-0
    [11] Huang SH, Huang AC, Wang CC, et al. Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control[J]. Thorac Cancer, 2019, 10: 2274-2281. doi:  10.1111/1759-7714.13221
    [12] Nishio M, Felip E, Orlov S, et al. Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase Ⅱ Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC[J]. J Thorac Oncol, 2020, 15: 609-617. doi:  10.1016/j.jtho.2019.11.006
    [13] Soria JC, Tan DSW, Chiari R, et al. First-line Ceritinib Versus Platinum-Based Chemotherapy in Advanced ALK-rearranged Non-Small-Cell Lung Cancer (ASCEND-4): A Randomised, Open-Label, Phase 3 Study[J]. Lancet, 2017, 389: 917-929. doi:  10.1016/S0140-6736(17)30123-X
    [14] Cho BC, Kim DW, Bearz A, et al. ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken With a Low-Fat Meal Versus 750 mg in Fasted State in Patients With Anaplastic Lymphoma Kinase (ALK)-Rearran-ged Metastatic Non-Small Cell Lung Cancer (NSCLC)[J]. J Thorac Oncol, 2017, 12: 1357-1367. doi:  10.1016/j.jtho.2017.07.005
    [15] Cho BC, Obermannova R, Bearz A, et al. Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study[J]. J Thorac Oncol, 2019, 14: 1255-1265. doi:  10.1016/j.jtho.2019.03.002
    [16] Huber RM, Hansen KH, Paz-Ares Rodríguez L, et al. Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial[J]. J Thorac Oncol, 2020, 15: 404-415. doi:  10.1016/j.jtho.2019.11.004
    [17] Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase Ⅲ ALTA-1L Trial[J]. J Clin Oncol, 2020, 38: 3592-3603. doi:  10.1200/JCO.20.00505
    [18] Zhu VW, Lin YT, Kim DW, et al. An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC[J]. J Thorac Oncol, 2020, 15: 1484-1496. doi:  10.1016/j.jtho.2020.04.019
    [19] Baldacci S, Besse B, Avrillon V, et al. 1303P Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort[J]. Ann Oncol, 2020, 31: 865-874. doi:  10.1016/j.annonc.2020.08.1663
    [20] Liang H, Wang M. MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis[J]. Onco Targets Ther, 2020, 13: 2491-2510. doi:  10.2147/OTT.S231257
    [21] Recondo G, Che J, Jänne PA, et al. Targeting MET Dysregulation in Cancer[J]. Cancer Discov, 2020, 10: 922-934. doi:  10.1158/2159-8290.CD-19-1446
    [22] Schuler M, Berardi R, Lim WT, et al. Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase Ⅰ trial[J]. Ann Oncol, 2020, 31: 789-797. doi:  10.1016/j.annonc.2020.03.293
    [23] Bang YJ, Su WC, Schuler M, et al. Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts[J]. Cancer Sci, 2020, 111: 536-547. doi:  10.1111/cas.14254
    [24] Heist RS, Wolf J, Seto T, et al. OA01.07 Capmatinib (INC280) in METΔEX14-Mutated Advanced NSCLC: Efficacy Data from the Phase 2 Geometry MONO-1 Study[J]. J Thorac Oncol, 2019, 14: S1126-S1138. http://www.sciencedirect.com/science/article/pii/S1556086419333490
    [25] Wolf J, Neal JW, Mansfield AS, et al. 1346P Comparison of clinical outcomes of patients with METΔex14 NSCLC treated with first-line capmatinib in the GEOMETRY mono-1 study with those of a cohort of real-world patients[J]. Ann Oncol, 2020, 31: S863-S874. doi:  10.1016/j.annonc.2020.08.1660
    [26] Goodwin K, Ledezma B, Heist R, etal. MO01.04 Management of Selected Adverse Events With Capmatinib: Institutional Experiences From the GEOMETRY Mono-1 Trial[J]. J Thorac Oncol, 2021, 16: S16-S17. http://www.sciencedirect.com/science/article/pii/S1556086420309187
    [27] Camidge D, Janku F, Bueno A, et al. 1490PDA phase Ⅰa/Ⅱa trial of Sym015, a MET antibody mixture, in patients with advanced solid tumours[J]. Ann Oncol, 2019, 30: 1128-1132. http://www.researchgate.net/publication/336192491_1490PDA_phase_IaIIa_trial_of_Sym015_a_MET_antibody_mixture_in_patients_with_advanced_solid_tumours
    [28] Camidge D, Janku F, Alejandro MB, et al. Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14Δ)[J]. J Clin Oncol, 2020, 38: 9510-9519. doi:  10.1200/JCO.2020.38.15_suppl.9510
    [29] Gu Y, Sai Y, Wang J, et al. Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor[J]. Eur J Pharm Sci, 2019, 136: 104938. doi:  10.1016/j.ejps.2019.05.016
    [30] Sequist LV, Han JY, Ahn MJ, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study[J]. Lancet Oncol, 2020, 21: 373-386. doi:  10.1016/S1470-2045(19)30785-5
    [31] Shun L, Jian F, Xingya L, et al. Phase Ⅱ study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+)[J]. J Clin Oncol, 2020, 38: 9519-9529. doi:  10.1200/JCO.2020.38.15_suppl.9519
    [32] Gan HK, Millward M, Hua Y, et al. First-in-Human Phase Ⅰ Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity[J]. Clin Cancer Res, 2019, 25: 4924-4932. doi:  10.1158/1078-0432.CCR-18-1189
    [33] Wu YL, Cheng Y, Zhou J, et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial[J]. Lancet Respir Med, 2020, 8: 1132-1143. doi:  10.1016/S2213-2600(20)30154-5
    [34] Paik P, Cortot A, Felip E, et al. A phase Ⅱ trial of tepotinib in patients with non-small cell lung cancer (NSCLC) harboring MET alterations: The VISION study[J]. Ann Oncol, 2019, 30: ii66-ii78. http://www.sciencedirect.com/science/article/pii/S0923753419301310
    [35] Markham A. Tepotinib: First Approval[J]. Drugs, 2020, 80: 829-833. doi:  10.1007/s40265-020-01317-9
    [36] Costa RLB, Czerniecki BJ. Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond[J]. NPJ Breast Cancer, 2020, 6: 2784-2795. http://www.researchgate.net/publication/339882217_Clinical_development_of_immunotherapies_for_HER2_breast_cancer_a_review_of_HER2-directed_monoclonal_antibodies_and_beyond
    [37] Xu F, Yang G, Xu H, et al. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China[J]. Thorac Cancer, 2020, 11: 679-685. doi:  10.1111/1759-7714.13317
    [38] Tsurutani J, Park H, DoiT, et al. OA02.07 Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or-Mutated Advanced Non-Small-Cell Lung Cancer[J]. J Thorac Oncol, 2018, 13: S324. http://www.sciencedirect.com/science/article/pii/S1556086418312024
    [39] Smit E, Nakagawa K, Nagasaka M, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01[J]. J Clin Oncol, 2020, 38: 9504. doi:  10.1200/JCO.2020.38.15_suppl.9504
  • 加载中
计量
  • 文章访问数:  45
  • HTML全文浏览量:  2
  • PDF下载量:  9
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-07-22
  • 录用日期:  2020-10-14
  • 网络出版日期:  2020-12-16
  • 刊出日期:  2021-05-30

目录

    /

    返回文章
    返回